2023 Q2 Form 10-Q Financial Statement

#000149315223016642 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $9.000K $10.00K $5.000K
YoY Change -25.0% 100.0% -91.07%
Cost Of Revenue $5.000K $1.000K $1.000K
YoY Change -16.67% 0.0% -66.67%
Gross Profit $4.000K $9.000K $4.000K
YoY Change -33.33% 125.0% -92.45%
Gross Profit Margin 44.44% 90.0% 80.0%
Selling, General & Admin $1.730M $1.993M $1.660M
YoY Change 29.3% 20.06% -17.9%
% of Gross Profit 43250.0% 22144.44% 41500.0%
Research & Development $160.0K $174.0K $363.0K
YoY Change -38.22% -52.07% 24.74%
% of Gross Profit 4000.0% 1933.33% 9075.0%
Depreciation & Amortization $32.00K $33.00K $33.00K
YoY Change -3.03% 0.0% 0.0%
% of Gross Profit 800.0% 366.67% 825.0%
Operating Expenses $1.890M $2.167M $2.056M
YoY Change 18.35% 5.4% -12.36%
Operating Profit -$1.886M -$2.158M -$2.052M
YoY Change 18.54% 5.17% -10.51%
Interest Expense $792.0K $1.100M -$571.0K
YoY Change -191.77% -292.64% 134.98%
% of Operating Profit
Other Income/Expense, Net -$793.0K -$1.127M -$84.00K
YoY Change -22.78% 1241.67% -119.22%
Pretax Income -$2.679M -$3.285M -$2.707M
YoY Change 2.33% 21.35% 35.83%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.669M -$3.277M -$2.706M
YoY Change 1.95% 21.1% 29.6%
Net Earnings / Revenue -29655.56% -32770.0% -54120.0%
Basic Earnings Per Share -$0.07 $0.77
Diluted Earnings Per Share -$0.07 -$0.09 -$71.32K
COMMON SHARES
Basic Shares Outstanding 37.95M shares 37.95M shares 37.94M shares
Diluted Shares Outstanding 37.95K shares 8.569M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $261.0K $280.0K $448.0K
YoY Change -62.82% -37.5% -44.62%
Cash & Equivalents $261.0K $280.0K $448.0K
Short-Term Investments
Other Short-Term Assets $1.083M $1.461M $1.381M
YoY Change 7.12% 5.79% 7.47%
Inventory
Prepaid Expenses
Receivables $6.000K $6.000K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.350M $1.747M $1.829M
YoY Change -21.74% -4.48% -14.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $673.0K $705.0K
YoY Change -16.29%
Long-Term Investments
YoY Change
Other Assets $50.00K $50.00K $50.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $10.93M $10.78M $887.0K
YoY Change 1179.51% 1115.78% -12.87%
TOTAL ASSETS
Total Short-Term Assets $1.350M $1.747M $1.829M
Total Long-Term Assets $10.93M $10.78M $887.0K
Total Assets $12.28M $12.53M $2.716M
YoY Change 376.04% 361.38% -14.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $506.0K $707.0K $501.0K
YoY Change 214.29% 41.12% 35.41%
Accrued Expenses $256.0K $359.0K $596.0K
YoY Change -50.86% -39.77% -28.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.94M $20.04M $6.657M
YoY Change 229.26% 201.07% 229.55%
Total Short-Term Liabilities $24.51M $22.53M $10.10M
YoY Change 169.73% 123.04% 157.04%
LONG-TERM LIABILITIES
Long-Term Debt $10.07M $10.01M $4.208M
YoY Change 49.02% 137.9% -21.11%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.07M $10.01M $4.208M
YoY Change 49.02% 137.9% -21.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.51M $22.53M $10.10M
Total Long-Term Liabilities $10.07M $10.01M $4.208M
Total Liabilities $34.57M $32.54M $14.26M
YoY Change 118.25% 128.11% 54.66%
SHAREHOLDERS EQUITY
Retained Earnings -$122.2M -$119.5M
YoY Change 10.02%
Common Stock $4.000K $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$22.18M -$19.89M -$11.55M
YoY Change
Total Liabilities & Shareholders Equity $12.28M $12.53M $2.716M
YoY Change 376.04% 361.38% -14.05%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.669M -$3.277M -$2.706M
YoY Change 1.95% 21.1% 29.6%
Depreciation, Depletion And Amortization $32.00K $33.00K $33.00K
YoY Change -3.03% 0.0% 0.0%
Cash From Operating Activities -$2.019M -$1.865M -$1.636M
YoY Change 15.64% 14.0% -37.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$10.00M $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$10.00M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.000M $11.50M 1.500M
YoY Change 0.0% 666.67% -39.9%
NET CHANGE
Cash From Operating Activities -2.019M -$1.865M -1.636M
Cash From Investing Activities 0.000 -$10.00M
Cash From Financing Activities 2.000M $11.50M 1.500M
Net Change In Cash -19.00K -$365.0K $0.00
YoY Change -107.48% -100.0%
FREE CASH FLOW
Cash From Operating Activities -$2.019M -$1.865M -$1.636M
Capital Expenditures
Free Cash Flow -$1.865M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001708599
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q1 AGE Payment To Acquire Loan Facilities
PaymentToAcquireLoanFacilities
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
usd
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2021Q4 AGE Warrant Liability
WarrantLiability
usd
CY2022 AGE Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
usd
CY2022 AGE Unrealized Loss On Change On Other Than Options
UnrealizedLossOnChangeOnOtherThanOptions
shares
CY2022 AGE Unrealized Loss On Change In Fair Value Of Warrants Per Share
UnrealizedLossOnChangeInFairValueOfWarrantsPerShare
CY2023Q1 AGE Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
usd
CY2023Q1 AGE Unrealized Loss On Change On Other Than Options
UnrealizedLossOnChangeOnOtherThanOptions
shares
CY2023Q1 AGE Unrealized Loss On Change In Fair Value Of Warrants Per Share
UnrealizedLossOnChangeInFairValueOfWarrantsPerShare
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1 us-gaap Accelerated Share Repurchases Final Price Paid Per Share
AcceleratedShareRepurchasesFinalPricePaidPerShare
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
CY2023Q1 us-gaap Short Term Debt Refinanced Amount
ShortTermDebtRefinancedAmount
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
1-38519
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
AgeX Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1436829
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1101 Marina Village Parkway
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 201
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Alameda
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
AGE
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37951261 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
280000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1461000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1804000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1747000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2453000 usd
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
705000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
738000 usd
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94501
CY2023Q1 dei City Area Code
CityAreaCode
(510)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
671-8370
CY2023Q1 us-gaap Notes And Loans Receivable Gross Noncurrent
NotesAndLoansReceivableGrossNoncurrent
10029000 usd
CY2023Q1 us-gaap Assets
Assets
12531000 usd
CY2022Q4 us-gaap Assets
Assets
3241000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1262000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1034000 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
20042000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7646000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
141000 usd
CY2023Q1 AGE Warrant Liability
WarrantLiability
347000 usd
CY2022Q4 AGE Warrant Liability
WarrantLiability
180000 usd
CY2023Q1 AGE Insurance Premium Liability And Other Current Liabilities
InsurancePremiumLiabilityAndOtherCurrentLiabilities
730000 usd
CY2022Q4 AGE Insurance Premium Liability And Other Current Liabilities
InsurancePremiumLiabilityAndOtherCurrentLiabilities
1077000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22525000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10078000 usd
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
10011000 usd
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
10478000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
32536000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
20556000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37951000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37951000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37949000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37949000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
99589000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98994000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119487000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116210000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-19894000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-17212000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-111000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-103000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-20005000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17315000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12531000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3241000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1000 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
1000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
9000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
4000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
174000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
396000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1993000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1660000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2167000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2056000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2158000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2052000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1100000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
571000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
30000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
87000 usd
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3000 usd
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1127000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-655000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3285000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2707000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3277000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2706000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37950000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37942000 shares
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3285000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2707000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3285000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2707000 usd
CY2023Q1 AGE Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations
LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations
8000 usd
CY2022Q1 AGE Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations
LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations
1000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3277000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2706000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17315000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
526000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
70000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3285000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-20005000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-20005000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-11875000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-11875000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
178000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
2575000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
239000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2707000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-11591000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-11591000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3277000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2706000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
30000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
87000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1057000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
544000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
70000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
239000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
3000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-25000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-314000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-243000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
205000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
207000 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
61000 usd
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
19000 usd
CY2023Q1 us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
-353000 usd
CY2022Q1 us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
-325000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
6000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1865000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1636000 usd
CY2023Q1 AGE Payment To Acquire Loan Facilities
PaymentToAcquireLoanFacilities
10000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000000 usd
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
11500000 usd
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1500000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11500000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1500000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-365000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-136000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
695000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
634000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
330000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
498000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119500000 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
300000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zaM1gxMSKd7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zhfQYYPaI1oi">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of our embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for discussion on estimated change in fair value of warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zuaAiyZJqWZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_znJa8AixCHx4">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. To date, AgeX has not experienced any losses on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, <i>Convertible Note Receivable </i>and 5, <i>Related Party Transactions</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Secured Debt
SecuredDebt
10000000 usd
CY2023Q1 AGE Warrant Liability
WarrantLiability
347000 usd
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
105000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
280000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645000 usd
CY2023Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
50000 usd
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
50000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
330000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
695000 usd
CY2023Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2023Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1312000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1312000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
607000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
574000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
705000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
738000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
98000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
131000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
131000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
132000 usd
CY2022Q4 AGE Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
213000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
705000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
707000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
568000 usd
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
196000 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
193000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
359000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
273000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1262000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1034000 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
250000 usd
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9600657 shares
CY2023Q1 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
250000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000000 usd
CY2023Q1 AGE Common Stock Outstanding Percentage
CommonStockOutstandingPercentage
0.85 pure
CY2023Q1 us-gaap Secured Debt
SecuredDebt
10000000 usd
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2000000000 usd
CY2022 AGE Changes In Fair Value
ChangesInFairValue
225000 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
500000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
454545 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.3960
CY2022Q4 AGE Warrant Liability
WarrantLiability
180000 usd
CY2023Q1 AGE Changes In Fair Value
ChangesInFairValue
30000 usd
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1000000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
756426 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.4593
CY2023Q1 AGE Warrant Liability
WarrantLiability
347000 usd
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2000000000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
30000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
87000 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37951261 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37951261 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37949196 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37949196 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
14000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
7000 usd
CY2023Q1 AGE Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
2000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
239000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.798
CY2022Q1 us-gaap Accelerated Share Repurchases Final Price Paid Per Share
AcceleratedShareRepurchasesFinalPricePaidPerShare
0.798
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M7D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3096 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0162 pure
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 AGE Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
2000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
178000 usd
CY2023Q1 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
663000 usd
CY2022Q1 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
4103000 usd
CY2022Q1 us-gaap Short Term Debt Refinanced Amount
ShortTermDebtRefinancedAmount
7160000 usd
CY2020Q2 AGE Loss Contingency Description
LossContingencyDescription
On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
2000000 usd

Files In Submission

Name View Source Status
0001493152-23-016642-index-headers.html Edgar Link pending
0001493152-23-016642-index.html Edgar Link pending
0001493152-23-016642.txt Edgar Link pending
0001493152-23-016642-xbrl.zip Edgar Link pending
age-20230331.xsd Edgar Link pending
ex10-9.htm Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
age-20230331_cal.xml Edgar Link unprocessable
age-20230331_def.xml Edgar Link unprocessable
age-20230331_lab.xml Edgar Link unprocessable
age-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending